WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 12, Issue 17, 618-632. Review Article ISSN 2277– 7105

ADVANCES IN PERSONALIZED MEDICINE: HARNESSING GENOMICS AND PRECISION THERAPEUTICS

Nihar Ranjan Kar*

Centurion University of Technology and Management, Gopalpur, Balasore, Odisha, India.

Article Received on
10 August 2023,

Revised on 31 August 2023,
Accepted on 20 Sept. 2023

DOI: 10. 20959/wjpr202317-29780

***Corresponding Author**
Nihar Ranjan Kar
Centurion University of Technology and Management, Gopalpur, Balasore, Odisha, India.

ABSTRACT

The integration of precision therapies and genomics has transformed the field of personalized medicine. It enables customized treatment based on a patient's unique genetic profile, environmental factors, and lifestyle choices. This approach enhances the efficacy of therapy, reduces adverse effects and proactively prevents the onset of illnesses. Despite some hurdles and limitations, personalized medicine has significant potential and is poised to revolutionize the healthcare sector through ongoing research and development efforts. Pharmacogenomics, a methodology that improves medicine selection and dosage, has played a crucial role. This paper examines the potential benefits of personalized medicine in enhancing patient outcomes and shaping the healthcare industry. It emphasizes the need for ongoing research and widespread implementation of these innovations.

KEYWORDS: Personalized medicine, genomics, precision therapeutics, pharmacogenomics, healthcare, genetic makeup, individualized treatment.

INTRODUCTION

Traditional medical practices have been standardized and untailored, leading to ineffective treatments, adverse side effects, and drug resistance.[1] Personalized medicine, a modern approach, considers a person's unique genetic makeup, environmental factors, and lifestyle choices.[2] This approach can improve treatment effectiveness, decrease side effects, and prevent illnesses proactively.[3] Advances in genomics and precision therapeutics have made personalized medicine possible, but challenges and limitations still exist.[4] Genomics studies genes and their impact on treatment response, while pharmacogenomics studies how genes affect medication response. Precision therapeutics uses targeted therapies with specific

disease-related molecules, resulting in increased efficacy and fewer side effects.[5] This revolutionary shift in healthcare focuses on a person's unique genetic makeup, environmental factors, and lifestyle, revolutionizing disease management and preventive strategies.[6]

GENOMICS AND ITS ROLE IN PERSONALIZED MEDICINE

The genetic information within the human genome can significantly impact an individual's susceptibility to various diseases and their response to treatments.[7] Thanks to the field of genomics, which studies an organism's genetic makeup, medicine has transformed by gaining critical insights into the causes of diseases and the development of new treatments.[8] Personalized medicine, which uses genomics, can pinpoint genetic variations linked to particular diseases.[9] This approach enables doctors to predict a patient's likelihood of developing the disease and select the most effective treatment.[10] The Human Genome Project was instrumental in modern genomics, allowing researchers to identify genetic variations associated with diseases and drug responses.[11] Personalized medicine is a patient-centred approach considering an individual's genes, lifestyle, and environmental differences.[12] The goal is to optimize healthcare interventions by delivering targeted and effective treatments, leading to better patient outcomes and fewer adverse effects.[13] In contrast to traditional medicine, which typically employs a "one-size-fits-all" approach, personalized medicine offers a superior alternative that can provide more accurate and effective treatment.[14]

PHARMACOGENOMICS

Pharmacogenomics is a significant field in personalized medicine since it investigates the connection between genes and drugs.[15] This study focuses on how genetic variations impact drug metabolism, efficacy, and potential adverse reactions.[16] By utilizing this information, healthcare professionals can determine the most suitable drugs and dosages for each patient, improving treatment outcomes and reducing adverse drug reactions.[17] Genetic variation can affect drug response in various ways, such as changing a person's ability to metabolize a drug, influencing the amount of drug that enters the bloodstream, or affecting the drug's interaction with target receptors.[18] Pharmacogenomics has been a crucial part of drug development and prescribing practices, with genetic tests that can identify a patient's poor, intermediate, or extensive drug metabolizer.[19] This allows for personalized dosages that optimize therapeutic benefits while minimizing adverse effects. Pharmacogenomics has applications in various medical specialties, including oncology, cardiology, psychiatry, and

infectious diseases. It is a practical approach proven to reduce adverse drug reactions and improve medication efficacy.[20]

PRECISION THERAPEUTICS

Precision Therapeutics is a groundbreaking approach to developing targeted therapies for various diseases. It involves leveraging genomics, proteomics, and molecular data to revolutionize how we combat illnesses.[21] By targeting specific molecules responsible for a disease, precision therapeutics can enhance treatment effectiveness and reduce side effects compared to traditional therapies.[22] This innovative approach has demonstrated remarkable promise in treating complex diseases like cancer, cardiovascular disorders, and rare genetic conditions. Precision therapeutics encompass monoclonal antibodies, small molecule inhibitors, and gene therapies, presenting significant strides in the field.[23] These therapies have effectively treated various conditions, with improved outcomes in specific patient subgroups. We can pinpoint specific biomarkers that drive disease development and progression by employing molecular biology and genomics, leading to personalized and more effective treatments.[24] Precision Therapeutics has exhibited considerable potential across different medical domains, including oncology, neurology, and rare genetic disorders.[25]

AI in Precision Therapeutics

Integrating artificial intelligence (AI) within precision medicine has garnered significant attention and interest among pharmaceutical researchers.[26] The utilization of AI in precision medicine holds immense potential for revolutionizing the field and enhancing patient care. Advanced algorithms and machine learning techniques are utilized to gain an advantage.[27] Artificial intelligence has ushered in a transformative paradigm shift in precision medicine. Machine learning algorithms are extensively employed in the field of genomic sequencing to effectively analyze and derive meaningful insights from the copious amounts of data that patients and healthcare institutions are continuously recording.[28] AI methodologies are employed within precision cardiovascular medicine to comprehensively comprehend the intricate interplay between genotypes and phenotypes about preexisting ailments. This facilitates the enhancement of patient care standards, fosters the attainment of optimal cost-effectiveness, and effectively curtails readmission and mortality rates.[29] In a recent publication from 2021, it was elucidated that the implementation of machine learning techniques demonstrated promising capabilities in prognosticating the outcomes of Phase III clinical trials, specifically about the treatment of prostate cancer. The findings revealed an

impressive accuracy rate of 76% in the predictions above.[30] The statement above posits that the utilization of clinical trial data holds promises as a viable resource for developing machine learning-driven tools in precision medicine.[31] The potential vulnerability of precision medicine to nuanced manifestations of algorithmic bias is a matter of concern. The coexistence of numerous input fields populated by multiple observers may engender distortions in the comprehension and interpretation of data.[32] A recent publication in 2020 has demonstrated that implementing machine learning models tailored to a specific population, such as training models exclusively for Black individuals with cancer, can result in notably enhanced performance compared to models that are not population-specific.[33]

Initiative for Precision Medicine

The Precision Medicine Initiative aims to personalize medical treatments according to unique patient characteristics, revolutionizing healthcare and improving outcomes.[34] President Obama announced the initiative in his 2015 State of the Union address, and $215 million was allocated towards its implementation.[35] The initiative's primary objective was to enhance cancer genomics for better preventive measures and treatment. In the long term, the initiative aimed to establish a nationwide research network and undertake a comprehensive cohort study involving one million individuals to augment our understanding of health and disease.[36] In 2016, the initiative was rebranded as "All of Us," an initial pilot program that successfully enrolled around 10,000 individuals by January 2018.[37]

Precision Healthcare Implications

Precision medicine involves customizing medical treatments to a patient's unique genetic, environmental, and lifestyle factors, making it a highly personalized approach to healthcare. By analyzing these factors, healthcare providers can comprehensively understand a patient's health and make informed decisions about their care.[38] This approach enhances prognostic capabilities, enabling providers to detect and prevent diseases earlier. Precision medicine also recommends novel therapeutic agents with improved therapeutic outcomes, avoiding prescription drugs with anticipated adverse effects. Patient care quality can be improved by optimizing the efficiency and efficacy of pharmaceutical clinical trials.[39]

USES

Precision medicine is a cutting-edge medical approach that tailors' treatments to patients' needs and characteristics. By identifying early warning signs, this innovative approach can suggest new and effective therapies that improve care quality.[40]

Action and verdict

Personalized medicine is crucial in pharmaceutical research, involving DNA analysis and tools like genotyping, pharmacogenomics, and companion diagnostics. This approach helps identify the efficacy and necessity of drugs for specific patient populations, potentially leading to FDA approval for ineffective drugs.[41] Genotyping can identify specific mutations in the CYP2D6 gene, enabling the selection of the most effective treatment strategy for women with estrogen receptor-positive breast cancer who exhibit resistance to Tamoxifen.[42] Pharmaceutical compounding synthesizes tailored pharmaceutical compounds for individual patients rather than producing standardized unit doses or fixed-dose combinations. Researchers are working on nanocarriers targeting specific disease sites using surface chemistry, advancing pharmaceutical science and improving patient outcomes.[43]

Theranostics

Theranostic is an innovative approach used in nuclear medicine involving molecular entities for diagnostic imaging and therapeutic intervention.[44] It combines the benefits of both therapeutics and diagnostics and primarily uses radionuclides such as gamma or positron emitters for SPECT or PET imaging and electron emitters for radiotherapy.[45] Some early examples of theranostics include radioactive iodine for prostate and thyroid cancer treatment, radio-labelled anti-CD20 antibodies for lymphoma management, Radium-223 for bone metastases, Lutetium-177 DOTATATE for neuroendocrine tumor treatment, and Lutetium-177 PSMA for prostate cancer mitigation.[46]

Respirational proteomics

Respiratory proteomics is a rapidly developing area of research that aims to comprehend the proteins involved in the respiratory system. These proteins are crucial in determining chronic pulmonary diseases like asthma, obstructive pulmonary disease, and lung cancer, which carry a significant burden of morbidity and mortality.[47] Unfortunately, early diagnosis of these disorders is often delayed, leading to poorer patient outcomes. Personalized medicine has emerged in recent years as a promising healthcare approach that harnesses innovative technologies to tailor treatments to patient's unique medical needs.[48] Proteomics is a powerful tool for investigating multiple protein expressions rather than focusing solely on a single biomarker. Proteomics examines biological specimens such as serum, blood cells, bronchoalveolar and nasal lavage fluids, and sputum in respiratory disorders to identify potential biomarkers.[49] By utilizing mass spectrometry and other advanced analytical

methodologies, scientists can profile and quantify protein expression in these samples, leading to the detection of numerous biomarkers associated with lung cancer.[50] These advancements enable the customization of treatment strategies to cater to individual patient's unique needs, and the scientific community has observed a growing body of evidence supporting the efficacy of proteomics in delivering precise therapeutic interventions for respiratory ailments.[51]

Malignancy Genomics

Cancer genomics is the study of genetic alterations and molecular characteristics associated with various types of cancer. Advancements in oncological research have revealed intricate genetic heterogeneity, indicating the presence of genetic diversity within a single neoplasm. This has led to the potential discovery of pharmaceutical interventions that may exhibit remarkable efficacy for specific cases characterized by distinct genetic profiles.[52] Personalized Onco-genomics, or "Oncogenomics," uses high-throughput sequencing techniques to comprehensively profile genes linked to cancer onset and progression. Oncogenomics has profound implications in pharmacotherapy, such as trastuzumab, a monoclonal antibody used to treat specific breast malignancies, and tyrosine kinase inhibitors like imatinib for chronic myeloid leukemia (CML).[53] Foundation Medicine's Foundation One CDx report provides tailored drug recommendations based on individual patients' genetic profiles. A substantial mutation burden indicates potential responsiveness to immunotherapy, and distinct mutation patterns have been observed in individuals with a history of exposure to cytotoxic cancer drugs.[54]

Inhabitants Transmission

Population screening involves examining a large group of individuals to identify health conditions or risk factors. Modern genomics techniques, proteomics methodologies, and imaging technologies enable the collection of molecular-level data.[55] This has proven effective in disease prognosis, particularly in cancer. Molecular biomarkers, particularly genomics, have shown promise in large-scale screening initiatives. Polygenic scores, a method used to estimate traits and disease susceptibility, have effectively treated various medical conditions.[56] However, these estimates could be more generalizable to other populations, necessitating more equitable genomics practices. Further translational research is needed to apply polygenic scores effectively in clinical settings.[57]

CONTESTS

The inherent complexities and obstacles arising within pharmaceutical research are commonly called challenges.[58] It is crucial to acknowledge the obstacles that come with personalized medicine. Various aspects, including intellectual property rights, reimbursement policies, patient privacy, data biases and confidentiality, and regulatory oversight, must be redefined and restructured to accommodate the changes personalized medicine brings to healthcare.[59] It is understandable for people to have concerns about using AI in the medical field. In a survey conducted in the UK, 63% of adults expressed discomfort with their data being utilized for medical purposes.[60] Moreover, personalized medicine faces challenges when analyzing acquired diagnostic data, such as genetic data obtained from next-generation sequencing, which requires computer-intensive data processing before its analysis.[61] To overcome these challenges, interdisciplinary cooperation between experts from specific research fields, such as medicine, clinical oncology, biology, and artificial intelligence, is essential in developing adequate tools that will accelerate the adoption of personalized medicine in various fields of medicine.[62]

Monitoring Errors

The FDA is integrating personalized medicine into its regulatory frameworks, as detailed in a 2013 report. Researchers are developing a genomic reference library to evaluate the authenticity and accuracy of sequencing platforms.[63] This library aims to ensure reliability in genomic analysis. One challenge in personalized medicine is establishing a robust framework for substantiating its efficacy compared to conventional treatment protocols. A universally accepted approach is needed for conducting such assessments.[64]

Intellectual Property Rights

Intellectual property rights protect the exclusive rights of individuals or entities over their creations or inventions, impacting investment and personalized medicine. In the US, the Supreme Court ruled in 2013 that naturally occurring genes are not eligible for patent protection, but synthetic DNA remains eligible.[65] The ongoing Patent Office evaluation focuses on personalized medicine, including the immunity of confirmatory secondary genetic tests. Opponents argue that patents hinder scientific progress, while proponents emphasize research exemption provisions and the importance of patents in incentivizing and safeguarding investments.[66]

Recompensate Policies

The pharmaceutical industry's reimbursement policies are crucial for fair compensation for healthcare providers and patients.[67] They should align with personalized medicine, considering factors like efficacy, cost-effectiveness, payment system management, and individual risk factors. A study on breast cancer found that diagnostic tests with high turnaround times cause delays in treatment, leading to patients bearing the financial burden.[68]

Patient Secrecy and Concealment

The importance of patient privacy and confidentiality in pharmaceutical research is paramount. The commercialization of personalized medicine raises concerns about the well-being of patients, particularly those with predispositions or non-responsiveness to specific treatments.[69] Privacy concerns are crucial throughout the process, from discovery to treatment protocols. 2008, the Genetic Information Nondiscrimination Act (GINA) was enacted to address these concerns. In 2015, the FDA permitted the marketing of a direct-to-consumer genetic carrier test for Bloom syndrome, highlighting the need for strict confidentiality protocols in personalized medicine.[70]

Statistics Predispositions

Data biases are a topic of concern within the realm of pharmaceutical research. The influence of data biases on personalized medicine is of paramount significance. It is imperative to ascertain that the genetic samples under examination encompass diverse populations.[71] This precautionary measure is implemented to circumvent the manifestation of analogous human biases employed in decision-making.[72] Suppose the algorithms devised to tailor medicine to individual patients exhibit bias. In that case, the resultant outcomes of said algorithms will also be biased due to the absence of genetic testing within specific populations.[73] To illustrate, the utilization of findings from the Framingham Heart Study, which exclusively involved individuals of Caucasian descent, has yielded biased predictions regarding the susceptibility to cardiovascular disease.[74] This stems from the fact that when these predictions were extrapolated to non-Caucasian populations, they tended to overestimate or underestimate cardiovascular disease-associated risks. The execution of the proposed course of action is of paramount importance in the context of our pharmaceutical research endeavours.[75]

Execution

Personalized medicine requires addressing several challenges, including limited human genome analysis, processing large amounts of genetic data, and analyzing genome-wide variations. Despite having access to a patient's data, healthcare providers may still need help analyzing the human genome, which can have errors of up to 30,000.[76] Despite low error rates, ensuring accuracy in data analysis is essential for discovery and verification. Genome-wide studies are also challenging due to the significant variation in the genome's size.[77] A centralized genome data and infrastructure database is necessary to implement a personalized medicine healthcare system. The Copenhagen Institute for Futures Studies and Roche have partnered to create the Future Proofing Healthcare initiative.[78] This initiative aims to develop a comprehensive personalized Health Index that evaluates the performance of various nations based on 27 indicators of personalized health.[79]

CONCLUSION

Personalized medicine is a transformative force in modern healthcare. With the help of genomics and precision therapeutics, it offers tailored treatment options to individual patients based on their genetic makeup and other personal factors. This approach improves patient outcomes, reduces adverse events, and enhances overall healthcare efficiency. Although some existing challenges, ongoing research and technological innovations offer promising solutions, paving the way for a future where personalized medicine becomes a routine part of clinical practice, benefiting patients worldwide. To embrace personalized medicine, a multidisciplinary approach is necessary, involving healthcare providers, researchers, policymakers, and patients as they collectively shape the future of healthcare. By adopting personalized medicine, we can revolutionize the healthcare landscape, improve patient outcomes, and significantly impact the world.

REFERENCES

1. Egnew TR. "Suffering, meaning, and healing: challenges of contemporary medicine". Annals of Family Medicine, 1 March 2009; **7**(2): 170–175.
2. Lesko LJ. "Personalized medicine: elusive dream or imminent reality?". Clinical Pharmacology and Therapeutics, June 2007; **81**(6): 807–186.
3. Priyadharshini VS, Teran LM. "Personalized Medicine in Respiratory Disease". Chapter Five - Personalized Medicine in Respiratory Disease: Role of Proteomics. Advances in Protein Chemistry and Structural Biology, 2016; 102: 115–146.

4. Xie J, Lee S, Chen X. Donev R (ed.). "Nanoparticle-based theranostic agents". Advanced Drug Delivery Reviews. Personalized Medicine. Academic Press, August, 2010; **62**(11): 1064–1079.
5. Yau, Tung on. "Precision treatment in colorectal cancer: Now and the future". JGH Open, October 2019; **3**(5): 361–369.
6. Jones DT, Banito A, Grünewald TG, Haber M, Jäger N, Kool M, et al. "Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours". Nature Reviews Cancer (Review), August 2019; **19**(8): 420–438.
7. Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. "Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals". Genome Research, January, 2014; **24**(1): 14–24.
8. Cenik C, Cenik ES, Byeon GW, Grubert F, Candille SI, Spacek D, et al. "Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans". Genome Research, November, 2015; **25**(11): 1610–1621.
9. Wu L, Candille SI, Choi Y, Xie D, Jiang L, Li-Pook-Than J, et al. "Variation and genetic control of protein abundance in humans". Nature, July, 2013; **499**(7456): 79–82.
10. Snyderman R. "Personalized health care: from theory to practice". Biotechnology Journal, August, 2012; **7**(8): 973–979.
11. Altmann A, Beerenwinkel N, Sing T, Savenkov I, Doumer M, Kaiser R, et al. "Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance". Antiviral Therapy, 2007; **12**(2): 169–178.
12. Blau CA, Liakopoulou E. "Can we deconstruct cancer, one patient at a time?". Opinion. Trends in Genetics. CellPress., 24 October 2012; **29**(1): 6–10.
13. Tavassoly I, Hu Y, Zhao S, Mariottini C, Boran A, Chen Y, et al. "Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses". Molecular Oncology, August, 2019; **13**(8): 1725–1743.
14. Garraway LA, Verweij J, Ballman KV. "Precision oncology: an overview". Journal of Clinical Oncology, May, 2013; **31**(15): 1803–1805.
15. Shrager J, Tenenbaum JM. "Rapid learning for precision oncology". Nature Reviews. Clinical Oncology, February, 2014; **11**(2): 109–118.
16. Fernandes BS, Berk M. "Staging in bipolar disorder: one step closer to precision psychiatry". Revista Brasileira de Psiquiatria, June, 2017; **39**(2): 88–89.

17. Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, et al. "Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease". Modern Pathology, April, 2013; **26**(4): 465–84.
18. Ogino, Shuji; Fuchs, Charles S; Giovannucci, Edward. "How many molecular subtypes? Implications of the unique tumor principle in personalized medicine". Expert Review of Molecular Diagnostics, July, 2012; **12**(6): 621–628.
19. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. "Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology". Oncogene, June, 2014; **33**(23): 2949–55.
20. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. "Complement factor H variant increases the risk of age-related macular degeneration". Science, April, 2005; **308**(5720): 419–421.
21. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, et al. "Clinical assessment incorporating a personal genome". Lancet, May 2010; **375**(9725): 1525–1535.
22. Huser V, Sincan M, Cimino JJ. "Developing genomic knowledge bases and databases to support clinical management: current perspectives". Pharmacogenomics and Personalized Medicine, 2014; **7**: 275–283.
23. Ashley EA. "The precision medicine initiative: a new national effort". JAMA, June 2015; **313**(21): 2119–20.
24. Belcher, Andrea; Mangelsdorf, Marie; McDonald, Fiona; Curtis, Caitlin; Waddell, Nicola; Hussey, Karen. "What does Australia's investment in genomics mean for public health?". Australian and New Zealand Journal of Public Health, June, 2019; **43**(3): 204–206.
25. Mesko B. "Expert Review of Precision Medicine and Drug Development". Journal Expert Review of Precision Medicine and Drug Development, 2017; **2**(5): 239–241.
26. Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. "Artificial Intelligence in Precision Cardiovascular Medicine". Journal of the American College of Cardiology, May, 2017; **69**(21): 2657–2664.
27. Bhargava, Hersh K.; Leo, Patrick; Elliott, Robin; Janowczyk, Andrew; Whitney, Jon; Gupta, Sanjay; Fu, Pingfu; Yamoah, Kosj; Khani, Francesca; Robinson, Brian D.; Rebbeck, Timothy R. "Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients". Clinical Cancer Research, 2020-04-15; **26**(8): 1915–1923.

28. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. "Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man". Clinical Pharmacology and Therapeutics, April, 1974; **15**(4): 424–30.
29. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose". The New England Journal of Medicine, June, 2005; **352**(22): 2285–93.
30. Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K, et al. "'Toxgnostics': an unmet need in cancer medicine". Nature Reviews. Cancer, June, 2014; **14**(6): 440–445.
31. Kelkar SS, Reineke TM. "Theranostics: combining imaging and therapy". Bioconjugate Chemistry, October, 2011; **22**(10): 1879–903.
32. Yahata N, Kasai K, Kawato M. "Computational neuroscience approach to biomarkers and treatments for mental disorders". Psychiatry and Clinical Neurosciences, April, 2017; **71**(4): 215–237.
33. Hamburg MA, Collins FS. "The path to personalized medicine". The New England Journal of Medicine, July 2010; **363**(4): 301–304.
34. Mancinelli L, Cronin M, Sadée W. "Pharmacogenomics: the promise of personalized medicine". AAPS PharmSci., 2000; **2**(1): 29–41.
35. Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. "Breast cancer in the personal genomics era". Current Genomics, May 2010; **11**(3): 146–61.
36. Soni A, Gowthamarajan K, Radhakrishnan A. "Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management". International Journal of Pharmaceutical Compounding, March 2018; **22**(2): 108–121.
37. Wang J, Poon C, Chin D, Milkowski S, Lu V, Hallows KR, Chung EJ. "Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery". Nano Research, 2018-10-01; **11**(10): 5584–5595.
38. Jump up to:[a b c] Langbein T, Weber WA, Eiber M. "Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine". Journal of Nuclear Medicine, September 2019; **60**(2): 13S–19S.
39. Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. "Radiotheranostics: a roadmap for future development". The Lancet. Oncology, March 2020; **21**(3): e146–e156.
40. Jadvar H, Chen X, Cai W, Mahmood U. "Radiotheranostics in Cancer Diagnosis and Management". Radiology, February, 2018; **286**(2): 388–400.

41. Pandey S, Giovenzana GB, Szikra D, Baranyai Z. "Chapter 11. Positron Emission Tomography (PET) Driven Theranostics". Metal Ions in Bio-Imaging Techniques. Springer, 2021; 315–346.
42. Priyadharshini VS, Teran LM. "Personalized Medicine in Respiratory Disease: Role of Proteomics". Advances in Protein Chemistry and Structural Biology, 2016; **102**: 115–416.
43. Priyadharshini VS, Teran LM. "Role of respiratory proteomics in precision medicine". In Faintuch J, Faintuch S (eds.). Precision Medicine for Investigators, Practitioners and Providers. Academic Press, 2020; 255–261.
44. Fujii K, Nakamura H, Nishimura T. "Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma". Expert Review of Proteomics, April, 2017; **14**(4): 373–386.
45. Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, et al. "Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors". Journal of Thoracic Oncology, January, 2012; **7**(1): 40–48.
46. Telli ML, Hunt SA, Carlson RW, Guardino AE. "Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility". Journal of Clinical Oncology, August 2007; **25**(23): 3525–3533.
47. Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, et al. "Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia". Annals of the New York Academy of Sciences, December 2004; **1028**(1): 423–431.
48. Pleasance E, Titmuss E, Williamson L, et al. "Pan-cancer analysis of advanced patient tumours reveals interactions between therapy and genomic landscapes". Nature Cancer, 2020; **1**(4): 452–468.
49. Duffy MJ. "Biochemical markers in breast cancer: which ones are clinically useful?". Clinical Biochemistry, July 2001; **34**(5): 347–352.
50. Piccart M, Lohrisch C, Di Leo A, Larsimont D. "The predictive value of HER2 in breast cancer". Oncology, 2001; 61,2(2): 73–82.
51. Baldus SE, Engelmann K, Hanisch FG. "MUC1 and the MUCs: a family of human mucins with impact in cancer biology". Critical Reviews in Clinical Laboratory Sciences, 1 January 2004; **41**(2): 189–231.

52. Cruz JA, Wishart DS. "Applications of machine learning in cancer prediction and prognosis". Cancer Informatics, February 2007; **2**: 59–77.
53. Williams MS. "Early Lessons from the Implementation of Genomic Medicine Programs". Annual Review of Genomics and Human Genetics, August 2019; **20**(1): 389–411.
54. Thomas M, Sakoda LC, Hoffmeister M, Peters U, Hsu L. "Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk". Am J Hum Genet, September 2020; **107**(3): 432–444.
55. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations". Nat Genet, September 2018; **50**(9): 1219–1224.
56. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. "Clinical use of current polygenic risk scores may exacerbate health disparities". Nat Genet, April 2019; **51**(4): 584–591.
57. Weldon CB, Trosman JR, Gradishar WJ, Benson AB, Schink JC. "Barriers to the use of personalized medicine in breast cancer". Journal of Oncology Practice, July 2012; **8**(4): e24-e31.
58. Char DS, Shah NH, Magnus D. "Implementing Machine Learning in Health Care - Addressing Ethical Challenges". The New England Journal of Medicine, March 2018; **378**(11): 981–983.
59. Chernew ME, Landrum MB. "Targeted Supplemental Data Collection - Addressing the Quality-Measurement Conundrum". The New England Journal of Medicine, March, 2018; **378**(11): 979–981.
60. Fernald GH, Capriotti E, Daneshjou R, Karczewski KJ, Altman RB. "Bioinformatics challenges for personalized medicine". Bioinformatics, July 2011; **27**(13): 1741–1748.
61. Check Hayden E. Promising gene therapies pose million-dollar conundrum. *Nature*, 2016; 534(7607): 305–306.
62. Fisher RA. The Correlation between Relatives on the Supposition of Mendelian Inheritance. *Philosophical Transactions of the Royal Society of Edinburgh*, 1918; 52: 399–433.
63. Carlsten C, Brauer M, Brinkman F, Brook J, Daley D, McNagny K, et al. Genes, the environment and personalized medicine: We need to harness both environmental and

genetic data to maximize personal and population health. *EMBO Rep.*, 2014; 15(7): 736–739.

64. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. *Br J Haematol*, 2014; 164(4): 469–680.
65. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. *Nat Rev Drug Discov*, 2013; 12(5): 358–369.
66. Chen Y, Elenee Argentinis JD, Weber G. IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research. *Clin Ther.*, 2016; 38(4): 688–701.
67. Song M, Ramakrishna S. Genome Editing in Stem Cells for Disease Therapeutics. *Mol Biotechnol*, 2018; 60(4): 329–338.
68. Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized Cancer Medicine: An Organoid Approach. *Trends Biotechnol*, 2018; 36(4): 358–371.
69. Schork NJ, Nazor K. Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond. *Adv Genet*, 2017; 97: 81–113.
70. Phillips KA, Douglas MP, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. *Value Health*, 2017; 20(1): 47–53.
71. Smarr L. Quantifying your body: a how-to guide from a systems biology perspective. *Biotechnol J.*, 2012; 7(8): 980–991.
72. Yurttas Beim P, Parfitt DE, Tan L, Sugarman EA, Hu-Seliger T, Clementi C, et al. At the dawn of personalized reproductive medicine: opportunities and challenges with incorporating multigene panel testing into fertility care. *J Assist Reprod Genet.*, 2017; 34(12): 1573–1576.
73. Bai J, Shen L, Sun H, Shen B. Physiological Informatics: Collection and Analyses of Data from Wearable Sensors and Smartphone for Healthcare. *Adv Exp Med Biol.*, 2017; 1028: 17–37.
74. Hogben L, Sim M. The self-controlled and self-recorded clinical trial for low-grade morbidity. *Br J Prev Soc Med.*, 1953; 7(4): 163–179.